Your Guide to Peptide Research

A small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction.

Abaloparatide (Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), engineered to bind the PTH1 receptor with a strong preference for its transient RG conformation rather than the long-lived R0 conformation favored by teriparatide. That receptor bias produces a shorter burst of signaling per injection - enough to drive osteoblast activity, but short enough to limit the bone resorption and calcium mobilization that follow a prolonged signal. In the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women, abaloparatide 80 mcg daily reduced new morphometric vertebral fractures by 86% versus placebo, alongside significant reductions in nonvertebral, major osteoporotic and clinical fractures. The FDA approved Tymlos in April 2017; in December 2021 the osteosarcoma boxed warning and the two-year cumulative lifetime limit were both removed from the label.

An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection.

A new class of antimicrobial peptides discovered and optimized using artificial intelligence platforms, with over 79 active compounds identified from a catalog of 863,498 AI-predicted sequences showing efficacy against multidrug-resistant pathogens.

An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback.

A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance.

Antibodies barely cross into the brain - which is why anti-amyloid Alzheimer's drugs need big infusions and still cause brain swelling. Roche's trontinemab flips the problem: it hitches a plaque-clearing antibody to a transferrin-receptor 'shuttle' that ferries it across the blood-brain barrier. Early data show some of the fastest, deepest amyloid clearance yet - with strikingly little ARIA. Here's what trontinemab is, how the Brainshuttle works, and why TRONTIER 1/2 and the new PrevenTRON prevention trial are the readouts to watch.

For years, cardiology chased a tantalizing idea: that quieting inflammation - not just lowering cholesterol - could prevent heart attacks. Ziltivekimab, Novo Nordisk's once-monthly anti-IL-6 antibody, was built to prove it. In July 2026 the pivotal ZEUS trial delivered a hard answer: the drug crushed inflammatory markers but did not cut cardiovascular events. Here's what ziltivekimab is, why it mattered, and what the surprising 'engagement-without-benefit' result means.

Vutrisiran silenced TTR and moved mortality. Eplontersen silences the same protein a different way - as an antisense oligonucleotide - and in July 2026 its huge ATTR cardiomyopathy trial, CARDIO-TTRansform, missed its primary endpoint. Here is how Ionis and AstraZeneca's once-monthly Wainua works, why it succeeded in nerves but stumbled in the heart, and what the monotherapy signal tells us about adding a silencer on top of tafamidis.